The Priority Review

Clinical trials Brief

Amgen registers Phase 3 trial of maridebart cafraglutide versus semaglutide in type 2 diabetes

The study, NCT07866066, plans to enroll 1300 participants and start on November 2, 2026. It plans to compare maridebart cafraglutide once monthly versus semaglutide once weekly as add-on therapy to metformin with or without a sodium-glucose cotransporter-2 inhibitor.

Primary source

ClinicalTrials.gov registry record, October 8, 2026

Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

Read the source clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation